Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma
- 14 June 2001
- journal article
- clinical trial
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 39 (1-2) , 115-123
- https://doi.org/10.1016/s1040-8428(01)00110-x
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- The Feasibility of Using Short-term Cultures of Ovarian Cancer Cells for Use as Autologous Tumor Cell Vaccines as Adjuvant Treatment of Advanced Ovarian CancerCancer Biotherapy & Radiopharmaceuticals, 1999
- THE USE OF SHORT-TERM CULTURES OF AUTOLOGOUS TUMOR CELLS FOR CANCER VACCINEJournal of Immunotherapy, 1999
- Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastasesCancer, 1999
- Clinical Experience with Autologous Tumor Cell Lines for Patient-Specific Vaccine Therapy in Metastatic MelanomaCancer Biotherapy & Radiopharmaceuticals, 1998
- Interferon-α and chemohormonal therapy for patients with advanced melanomaCancer, 1998
- Hybrid High-Dose Bolus/Continuous Infusion Interleukin-2 in Patients with Metastatic Renal Cell Carcinoma: A Phase II Trial of the National Biotherapy Study GroupCancer Biotherapy & Radiopharmaceuticals, 1997
- Why Event-Free Survival is Better than Tumor Response or other Measures of Survival as an Endpoint in Cancer TrialsCancer Biotherapy & Radiopharmaceuticals, 1996
- Inpatient continuous-infusion interleukin-2 in 788 patients with cancer the national biotherapy study group experienceCancer, 1993
- Melanoma tumor vaccine: Five-year follow-upJournal of Surgical Oncology, 1991
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958